Information Provided By:
Fly News Breaks for February 21, 2020
AMED
Feb 21, 2020 | 08:08 EDT
BMO Capital analyst Matt Borsch raised his price target on Amedisys to $215 but kept his Market Perform rating. The analyst notes that Q4 had "solid but mixed" results, with an earnings beat and a revenue miss due to the management's focus on implementation of PDGM and integration of CCH. Borsch adds that the stock is trading at a "relatively high valuation" that already embeds investor expectations for strong fundamental performance.
News For AMED From the Last 2 Days
AMED
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.